Search, Find and Buy Antibodies, ELISA Kits and Proteins.
Loading Loading
Order hotline:
phone +1 404 474 4654
fax +1 888 205 9894 (TF)
Details for Product No. ABIN264443

Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL) (AA 1-213), (N-Term) antibody

Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Synonyms HRCA1, RCA1, VHL1, pVHL
»Alternatives AA 1-213, N-Term
»Alternatives Human
»Alternatives Mouse
Clonality (Clone) Monoclonal ()
»Alternatives Un-conjugated
»Alternatives Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunoprecipitation (IP), Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
Pubmed 4 references available
Catalog no. ABIN264443
Quantity 0.1 mg
588.50 $   Plus shipping costs $45.00
Shipping to
Availability Will be delivered in 6 to 8 Business Days
Immunogen Hybridoma produced by the fusion of splenocytes from BALB/c mice immunized with arecombinant fusion protein containing amino acids 1-213 of human VHL and mousemyeloma p3-NS-1/Ag4-1 cells.
Clone Ig33
Isotype IgG1
Characteristics Synonyms: Von Hippel-Lindau disease tumor suppressor, Protein G7
Purification Purified
Alternative Name VHL
Background Alterations in the von Hippel-Lindau (VHL) gene are correlated with a diverse group ofneoplasms including hemangioblastoma, clear cell renal carcinoma (RCC), andpheochromocytoma. Molecular genetic studies suggest that VHL is a tumor-suppressorgene, correspondingly, reintroduction of a VHL complementary DNA (cDNA) into RCC cellsinhibits their ability to form tumors in nude mice. Two transcriptional elongation factors,Elongin B and C, are shown to bind in vitro and in vivo to a short, colinear region of the VHLprotein (pVHL) that is frequently mutated in human tumors. It is proposed that pVHLfunctions in vivo as a negative regulator of transcription elongation.
UniProt P40337
Research Area Hormones, Cytokines
Application Notes Western Blot (1 µg/ml). Immunoprecipitation (2 µg/mg of protein lysate). Immunohistochemistry on frozen and Formalin/paraffin embedded tissues (2-4 µg/ml). Positive Control: Carcinomas of kidney, lung, prostate, colon, breast, bladder and thyroid,cerebellar hemagioblastomas and pheochromocytoma. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions For Research Use only
Format Liquid
Concentration 1,0 mg/mL
Buffer PBS containing 0.08% Sodium Azide as preservative.
Preservative Sodium azide
Storage -20 °C
Storage Comment Store the antibody (in aliquots) at -20°C. Avoid repeated freezing and thawing. Shelf life: One year from despatch.
Expiry Date 12 months
Background publications Iliopoulos, Kibel, Gray et al.: "Tumour suppression by the human von Hippel-Lindau gene product." in: Nature medicine, Vol. 1, Issue 8, pp. 822-6, 1995 (PubMed).

Kibel, Iliopoulos, DeCaprio et al.: "Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C." in: Science (New York, N.Y.), Vol. 269, Issue 5229, pp. 1444-6, 1995 (PubMed).

Los, Jansen, Kaelin et al.: "Expression pattern of the von Hippel-Lindau protein in human tissues." in: Laboratory investigation; a journal of technical methods and pathology, Vol. 75, Issue 2, pp. 231-8, 1996 (PubMed).

Corless, Kibel, Iliopoulos et al.: "Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues." in: Human pathology, Vol. 28, Issue 4, pp. 459-64, 1997 (PubMed).

Alternatives for antigen "Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL)", type "Antibodies"
Hosts (66), (34), (8), (2)
Reactivities (103), (38), (37), (15), (12)
Applications (80), (43), (23), (17), (10), (7), (6), (5), (3)
Conjugates (7), (4), (3), (3), (3), (1), (1), (1), (1), (1), (1), (1), (1), (1)
Epitopes (9), (7), (6), (4), (3), (3), (2), (2), (2), (1), (1), (1), (1)